Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of Hexavalent DTaP-IPV-HB-PRP~T Vaccine in South African Infants
NCT00362336Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2006
- Primary completion
- May 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (3 arms), sponsored by Sanofi. Primary endpoint: Number of Participants With Seroprotection After Primary Series Vaccination. Started Aug 2006; status: completed.
02
Drugs
hexaxim
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on NCT00362336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00362336.